Top

Published in:

Open Access 01-12-2016 | Review

Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice

Authors: Minghuan Li, Xiaoli Zhang, Fen Zhao, Yijun Luo, Li Kong, Jinming Yu

Published in: Radiation Oncology | Issue 1/2016

Abstract

Esophageal carcinoma (EC) is characterized by a high rate of lymph node metastasis and its spread pattern is not always predictable. Chemoradiotherapy has an important role in the treatment of EC in both the inoperable and the pre-operative settings. However, regarding the target volume for radiation, different clinical practices exist. Theoretically, in addition to the clinical target volume administered to the gross lesion, it might seem logical to deliver a certain dose to the uninvolved regional lymph node area at risk for microscopic disease. However, in practice, it is difficult because of the intolerance of normal tissue to radiotherapy (RT), particularly if all regions containing the cervical, mediastinal, and upper abdominal nodes are covered. To date, the use of elective nodal irradiation (ENI) is still controversial in the field of radiotherapy. Some investigators use involved-field radiotherapy (IFRT) in order to reduce treatment-related toxicities. It is thought that micrometastases can be controlled, to some extent, by chemotherapy and the abscopal effects of radiation. It is the presence of overtly involved lymph nodes rather than the micrometastatic nodes negatively affects survival in patients with EC. In another hand, lymph nodes stationed near primary tumors also receive considerable incidental irradiation doses that may contribute to the elimination of subclinical lesions. These data indicate that an irradiation volume covering only the gross tumor is appropriate. When using ENI or IFRT, very few patients experience solitary regional node failure and out-of-field lymph node failure is not common. Primary tumor recurrence and distant metastases, rather than regional lymph node failure, affect the overall survival in patients with EC. The available evidence indicates that the use of ENI seems to prevent or delay regional nodal relapse rather than improve survival. In a word, these data suggest that IFRT is feasible in EC patients.

Ajani JA. Gastroesophageal cancers: progress and problems. J Natl Compr Cancer Netw. 2008;6(9):813–4.

Eslick GD. Epidemiology of esophageal cancer. Gastroenterol Clin North Am. 2009;38(1):17–25. doi:10.1016/j.gtc.2009.01.008. vii.CrossRefPubMed

Cooper JS, Guo MD, Herskovic A, Macdonald JS, Martenson Jr JA, Al-Sarraf M, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85–01). Radiation Therapy Oncology Group. JAMA. 1999;281(17):1623–7.CrossRefPubMed

Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, et al. INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol. 2002;20(5):1167–74.CrossRefPubMed

Higuchi K, Koizumi W, Tanabe S, Sasaki T, Katada C, Azuma M, et al. Current management of esophageal squamous-cell carcinoma in Japan and other countries. Gastrointest Cancer Res. 2009;3(4):153–61.PubMedCentralPubMed

Meng X, Wang J, Sun X, Wang L, Ye M, Feng P, et al. Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: a prospective, multicenter phase II trail. Radiother Oncol. 2013;109(2):275–80. doi:10.1016/j.radonc.2013.09.008.CrossRefPubMed

Gao XS, Qiao X, Wu F, Cao L, Meng X, Dong Z, et al. Pathological analysis of clinical target volume margin for radiotherapy in patients with esophageal and gastroesophageal junction carcinoma. Int J Radiat Oncol Biol Phys. 2007;67(2):389–96. doi:10.1016/j.ijrobp.2006.09.015.CrossRefPubMed

Button MR, Morgan CA, Croydon ES, Roberts SA, Crosby TD. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73(3):818–23. doi:10.1016/j.ijrobp.2008.04.062.CrossRefPubMed

Rosenzweig KE, Sura S, Jackson A, Yorke E. Involved-field radiation therapy for inoperable non small-cell lung cancer. J Clin Oncol. 2007;25(35):5557–61. doi:10.1200/jco.2007.13.2191.CrossRefPubMed

10.

Xia B, Chen GY, Cai XW, Zhao JD, Yang HJ, Fan M, et al. Is involved-field radiotherapy based on CT safe for patients with limited-stage small-cell lung cancer? Radiother Oncol. 2012;102(2):258–62. doi:10.1016/j.radonc.2011.10.003.CrossRefPubMed

11.

Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, et al. Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2014;89(1):49–58. doi:10.1016/j.ijrobp.2014.01.006.CrossRefPubMed

12.

Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, et al. Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys. 2014;89(4):854–62. doi:10.1016/j.ijrobp.2013.05.005.CrossRefPubMed

13.

Zhao KL, Ma JB, Liu G, Wu KL, Shi XH, Jiang GL. Three-dimensional conformal radiation therapy for esophageal squamous cell carcinoma: is elective nodal irradiation necessary? Int J Radiat Oncol Biol Phys. 2010;76(2):446–51. doi:10.1016/j.ijrobp.2009.02.078.CrossRefPubMed

14.

Zhang X, Li M, Meng X, Kong L, Zhang Y, Wei G, et al. Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. Radiat Oncol. 2014;9:64. doi:10.1186/1748-717x-9-64.PubMedCentralCrossRefPubMed

15.

Bedenne L, Michel P, Bouche O, Milan C, Mariette C, Conroy T, et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol. 2007;25(10):1160–8. doi:10.1200/jco.2005.04.7118.CrossRefPubMed

16.

Kawaguchi Y, Nishiyama K, Miyagi K, Suzuki O, Ito Y, Nakamura S. Patterns of failure associated with involved field radiotherapy in patients with clinical stage I thoracic esophageal cancer. Jpn J Clin Oncol. 2011;41(8):1007–12. doi:10.1093/jjco/hyr069.CrossRefPubMed

17.

Yamashita H, Omori M, Takenaka R, Okuma K, Kobayashi R, Ohtomo K, et al. Involved-field irradiation concurrently combined with nedaplatin/5-fluorouracil for inoperable esophageal cancer on basis of (18)FDG-PET scans: a phase II study. Radiother Oncol. 2014;113(2):182–7. doi:10.1016/j.radonc.2014.11.004.CrossRefPubMed

18.

Nishihira T, Sayama J, Ueda H, Sugawara K, Takano R, Sagawa J, et al. Lymph flow and lymph node metastasis in esophageal cancer. Surg Today. 1995;25(4):307–17.CrossRefPubMed

19.

Motoyama S, Maruyama K, Sato Y, Usami S, Nakatsu T, Saito H, et al. Status of involved lymph nodes and direction of metastatic lymphatic flow between submucosal and t2-4 thoracic squamous cell esophageal cancers. World J Surg. 2009;33(3):512–7. doi:10.1007/s00268-008-9781-8.CrossRefPubMed

20.

Kuge K, Murakami G, Mizobuchi S, Hata Y, Aikou T, Sasaguri S. Submucosal territory of the direct lymphatic drainage system to the thoracic duct in the human esophagus. J Thorac Cardiovasc Surg. 2003;125(6):1343–9.CrossRefPubMed

21.

Mizutani M, Murakami G, Nawata S, Hitrai I, Kimura W. Anatomy of right recurrent nerve node: why does early metastasis of esophageal cancer occur in it? Surg Radiol Anat. 2006;28(4):333–8. doi:10.1007/s00276-006-0115-y.CrossRefPubMed

22.

Tachimori Y, Nagai Y, Kanamori N, Hokamura N, Igaki H. Pattern of lymph node metastases of esophageal squamous cell carcinoma based on the anatomical lymphatic drainage system. Dis Esophagus. 2011;24(1):33–8. doi:10.1111/j.1442-2050.2010.01086.x.CrossRefPubMed

23.

Itoh Y, Huwa N. Simultaneous combination of chemotherapy using protracted infusion of low-dose cisplatin and 5-fluorouracil with radiotherapy. Relationship between the size of the irradiation field and hemotoxicity. Anticancer Res. 2003;23(2c):1709–11.PubMed

24.

Herskovic A, Martz K, al-Sarraf M, Leichman L, Brindle J, Vaitkevicius V, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992;326(24):1593–8. doi:10.1056/nejm199206113262403.CrossRefPubMed

25.

Ding X, Zhang J, Li B, Wang Z, Huang W, Zhou T, et al. A meta-analysis of lymph node metastasis rate for patients with thoracic oesophageal cancer and its implication in delineation of clinical target volume for radiation therapy. Br J Radiol. 2012;85(1019):e1110–9. doi:10.1259/bjr/12500248.PubMedCentralCrossRefPubMed

26.

Rice TW, Zuccaro Jr G, Adelstein DJ, Rybicki LA, Blackstone EH, Goldblum JR. Esophageal carcinoma: depth of tumor invasion is predictive of regional lymph node status. Ann Thorac Surg. 1998;65(3):787–92.CrossRefPubMed

27.

Shimada H, Nabeya Y, Matsubara H, Okazumi S, Shiratori T, Shimizu T, et al. Prediction of lymph node status in patients with superficial esophageal carcinoma: analysis of 160 surgically resected cancers. Am J Surg. 2006;191(2):250–4. doi:10.1016/j.amjsurg.2005.07.035.CrossRefPubMed

28.

van Vliet EP, Heijenbrok-Kal MH, Hunink MG, Kuipers EJ, Siersema PD. Staging investigations for oesophageal cancer: a meta-analysis. Br J Cancer. 2008;98(3):547–57. doi:10.1038/sj.bjc.6604200.PubMedCentralCrossRefPubMed

29.

Yuan S, Yu Y, Chao KS, Fu Z, Yin Y, Liu T, et al. Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. J Nucl Med. 2006;47(8):1255–9.PubMed

30.

Izbicki JR, Hosch SB, Pichlmeier U, Rehders A, Busch C, Niendorf A, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337(17):1188–94. doi:10.1056/nejm199710233371702.CrossRefPubMed

31.

Prenzel KL, Holscher AH, Drebber U, Agavonova M, Gutschow CA, Bollschweiler E. Prognostic impact of nodal micrometastasis in early esophageal cancer. Eur J Surg Oncol. 2012;38(4):314–8. doi:10.1016/j.ejso.2012.01.007.CrossRefPubMed

32.

Koenig AM, Prenzel KL, Bogoevski D, Yekebas EF, Bubenheim M, Faithova L, et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol. 2009;16(2):454–62. doi:10.1245/s10434-008-0169-7.CrossRefPubMed

33.

Nakamura T, Ide H, Eguchi R, Hayashi K, Ota M, Takasaki K. Clinical implications of lymph node micrometastasis in patients with histologically node-negative (pN0) esophageal carcinoma. J Surg Oncol. 2002;79(4):224–9. doi:10.1002/jso.10080.CrossRefPubMed

34.

Sato F, Shimada Y, Li Z, Watanabe G, Maeda M, Imamura M. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg. 2001;88(3):426–32. doi:10.1046/j.1365-2168.2001.01687.x.CrossRefPubMed

35.

Ma GW, Situ DR, Ma QL, Long H, Zhang LJ, Lin P, et al. Three-field vs two-field lymph node dissection for esophageal cancer: a meta-analysis. World J Gastroenterol. 2014;20(47):18022–30. doi:10.3748/wjg.v20.i47.18022.PubMedCentralPubMed

36.

van der Schaaf M, Johar A, Wijnhoven B, Lagergren P, Lagergren J. Extent of lymph node removal during esophageal cancer surgery and survival. J Natl Cancer Inst. 2015;107(5). doi:10.1093/jnci/djv043.

37.

Wong J, Weber J, Almhanna K, Hoffe S, Shridhar R, Karl R, et al. Extent of lymphadenectomy does not predict survival in patients treated with primary esophagectomy. J Gastrointest Surg. 2013;17(9):1562–8. doi:10.1007/s11605-013-2259-5. discussion 9.CrossRefPubMed

38.

Nishimaki T, Suzuki T, Suzuki S, Kuwabara S, Hatakeyama K. Outcomes of extended radical esophagectomy for thoracic esophageal cancer. J Am Coll Surg. 1998;186(3):306–12.CrossRefPubMed

39.

Rizk N, Venkatraman E, Park B, Flores R, Bains MS, Rusch V. The prognostic importance of the number of involved lymph nodes in esophageal cancer: implications for revisions of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2006;132(6):1374–81. doi:10.1016/j.jtcvs.2006.07.039.CrossRefPubMed

40.

Natsugoe S, Yoshinaka H, Shimada M, Sakamoto F, Morinaga T, Nakano S, et al. Number of lymph node metastases determined by presurgical ultrasound and endoscopic ultrasound is related to prognosis in patients with esophageal carcinoma. Ann Surg. 2001;234(5):613–8.PubMedCentralCrossRefPubMed

41.

Yamashita H, Okuma K, Wakui R, Kobayashi-Shibata S, Ohtomo K, Nakagawa K. Details of recurrence sites after elective nodal irradiation (ENI) using 3D-conformal radiotherapy (3D-CRT) combined with chemotherapy for thoracic esophageal squamous cell carcinoma--a retrospective analysis. Radiother Oncol. 2011;98(2):255–60. doi:10.1016/j.radonc.2010.10.021.CrossRefPubMed

42.

Onozawa M, Nihei K, Ishikura S, Minashi K, Yano T, Muto M, et al. Elective nodal irradiation (ENI) in definitive chemoradiotherapy (CRT) for squamous cell carcinoma of the thoracic esophagus. Radiother Oncol. 2009;92(2):266–9. doi:10.1016/j.radonc.2008.09.025.CrossRefPubMed

43.

Prenzel KL, Konig A, Schneider PM, Schnickmann C, Baldus SE, Schroder W, et al. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer. Ann Surg Oncol. 2007;14(2):954–9. doi:10.1245/s10434-006-9141-6.CrossRefPubMed

44.

Matsuyama J, Doki Y, Yasuda T, Miyata H, Fujiwara Y, Takiguchi S, et al. The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery. 2007;141(5):570–80. doi:10.1016/j.surg.2006.11.007.CrossRefPubMed

45.

Tsuchiya Y, Onda M, Sasajima K, Yamashita K, Nomura T, Makino H, et al. Effects of preoperative chemotherapy on metastatic lymph nodes in esophageal squamous cell carcinoma. Dis Esophagus. 2002;15(3):226–31.CrossRefPubMed

46.

Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol. 2009;10(7):718–26. doi:10.1016/s1470-2045(09)70082-8.PubMedCentralCrossRefPubMed

47.

Ahmed MM, Guha C, Hodge JW, Jaffee E. Immunobiology of radiotherapy: new paradigms. Radiat Res. 2014;182(2):123–5. doi:10.1667/rr13849.1.PubMedCentralCrossRefPubMed

48.

Ji K, Zhao L, Yang C, Meng M, Wang P. Three-dimensional conformal radiation for esophageal squamous cell carcinoma with involved-field irradiation may deliver considerable doses of incidental nodal irradiation. Radiat Oncol. 2012;7:200. doi:10.1186/1748-717x-7-200.PubMedCentralCrossRefPubMed

49.

Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39(10):638–43. doi:10.1093/jjco/hyp069.CrossRefPubMed

50.

Kaneko K, Ito H, Konishi K, Kurahashi T, Ito T, Katagiri A, et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer. 2003;88(1):18–24. doi:10.1038/sj.bjc.6600684.PubMedCentralCrossRefPubMed

51.

Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer. 2006;95(6):705–9. doi:10.1038/sj.bjc.6603328.PubMedCentralCrossRefPubMed

52.

Kato K, Nakajima TE, Ito Y, Katada C, Ishiyama H, Tokunaga SY, et al. Phase II study of concurrent chemoradiotherapy at the dose of 50.4 Gy with elective nodal irradiation for Stage II-III esophageal carcinoma. Jpn J Clin Oncol. 2013;43(6):608–15. doi:10.1093/jjco/hyt048.CrossRefPubMed

53.

Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17(9):2915–21.PubMed

54.

Nishimura Y, Suzuki M, Nakamatsu K, Kanamori S, Yagyu Y, Shigeoka H. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula. Int J Radiat Oncol Biol Phys. 2002;53(1):134–9.CrossRefPubMed

55.

Itoh Y, Fuwa N, Matsumoto A, Asano A, Morita K. Outcomes of radiotherapy for inoperable locally advanced (T4) esophageal cancer-retrospective analysis. Radiat Med. 2001;19(5):231–5.PubMed

56.

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84. doi:10.1056/NEJMoa1112088.CrossRefPubMed

57.

Rohatgi PR, Swisher SG, Correa AM, Wu TT, Liao Z, Komaki R, et al. Failure patterns correlate with the proportion of residual carcinoma after preoperative chemoradiotherapy for carcinoma of the esophagus. Cancer. 2005;104(7):1349–55. doi:10.1002/cncr.21346.CrossRefPubMed

58.

Lin SH, Wang J, Allen PK, Correa AM, Maru DM, Swisher SG, et al. A nomogram that predicts pathologic complete response to neoadjuvant chemoradiation also predicts survival outcomes after definitive chemoradiation for esophageal cancer. J Gastrointest Oncol. 2015;6(1):45–52. doi:10.3978/j.issn.2078-6891.2014.054.PubMedCentralPubMed

59.

Ishikawa H, Sakurai H, Tamaki Y, Nonaka T, Yamakawa M, Saito Y, et al. Radiation therapy alone for stage I (UICC T1N0M0) squamous cell carcinoma of the esophagus: indications for surgery or combined chemoradiotherapy. J Gastroenterol Hepatol. 2006;21(8):1290–6. doi:10.1111/j.1440-1746.2006.04089.x.CrossRefPubMed

60.

Okawa T, Tanaka M, Kita-Okawa M, Nishio M, Kikuchi Y, Shirato H, et al. Superficial esophageal cancer: multicenter analysis of results of definitive radiation therapy in Japan. Radiology. 1995;196(1):271–4. doi:10.1148/radiology.196.1.7784580.CrossRefPubMed

61.

Yamamoto S, Ishihara R, Motoori M, Kawaguchi Y, Uedo N, Takeuchi Y, et al. Comparison between definitive chemoradiotherapy and esophagectomy in patients with clinical stage I esophageal squamous cell carcinoma. Am J Gastroenterol. 2011;106(6):1048–54. doi:10.1038/ajg.2011.42.CrossRefPubMed

62.

Welsh J, Settle SH, Amini A, Xiao L, Suzuki A, Hayashi Y, et al. Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer. 2012;118(10):2632–40. doi:10.1002/cncr.26586.PubMedCentralCrossRefPubMed

63.

Versteijne E, van Laarhoven HW, van Hooft JE, van Os RM, Geijsen ED, van Berge Henegouwen MI, et al. Definitive chemoradiation for patients with inoperable and/or unresectable esophageal cancer: locoregional recurrence pattern. Dis Esophagus. 2014. doi:10.1111/dote.12215.PubMed

64.

Oppedijk V, van der Gaast A, van Lanschot JJ, van Hagen P, van Os R, van Rij CM, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32(5):385–91. doi:10.1200/JCO.2013.51.2186.CrossRefPubMed

65.

Di Fiore F, Lecleire S, Rigal O, Galais MP, Ben Soussan E, David I, et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol. 2006;12(26):4185–90.PubMedCentralPubMed

66.

Uno T, Isobe K, Kawakami H, Ueno N, Kobayashi H, Shimada H, et al. Efficacy and toxicities of concurrent chemoradiation for elderly patients with esophageal cancer. Anticancer Res. 2004;24(4):2483–6.PubMed

67.

Ma JB, Song YP, Yu JM, Zhou W, Cheng EC, Zhang XQ, et al. Feasibility of involved-field conformal radiotherapy for cervical and upper-thoracic esophageal cancer. Onkologie. 2011;34(11):599–604. doi:10.1159/000334194.CrossRefPubMed

68.

Nemoto K, Yamada S, Nishio M, Aoki M, Nakamura R, Matsumoto Y, et al. Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Anticancer Res. 2006;26(2b):1507–12.PubMed

69.

Liu M, Zhao K, Chen Y, Jiang GL. Evaluation of the value of ENI in radiotherapy for cervical and upper thoracic esophageal cancer: a retrospective analysis. Radiat Oncol. 2014;9:232. doi:10.1186/s13014-014-0232-4.PubMedCentralCrossRefPubMed

70.

Hsu FM, Lee JM, Huang PM, Lin CC, Hsu CH, Tsai YC, et al. Retrospective analysis of outcome differences in preoperative concurrent chemoradiation with or without elective nodal irradiation for esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2011;81(4):e593–9. doi:10.1016/j.ijrobp.2011.04.032.CrossRefPubMed

71.

Ishikura S, Nihei K, Ohtsu A, Boku N, Hironaka S, Mera K, et al. Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol. 2003;21(14):2697–702. doi:10.1200/jco.2003.03.055.CrossRefPubMed

72.

Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, et al. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014;15(3):305–14. doi:10.1016/S1470-2045(14)70028-2.CrossRefPubMed

Title: Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice
Authors: Minghuan Li
Xiaoli Zhang
Fen Zhao
Yijun Luo
Li Kong
Jinming Yu
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2016
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/s13014-016-0589-7

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2016

Regional hyperthermia combined with chemotherapy in paediatric, adolescent and young adult patients: current and future perspectives

Hyperbaric oxygen therapy for late radiation-induced tissue toxicity: prospectively patient-reported outcome measures in breast cancer patients

Outcomes of hypofractionated stereotactic body radiotherapy boost for intermediate and high-risk prostate cancer

Radiobiological impact of dose calculation algorithms on biologically optimized IMRT lung stereotactic body radiation therapy plans

Intensity modulated radiation therapy (IMRT) for sinonasal tumors: a single center long-term clinical analysis

A treatment planning study of proton arc therapy for para-aortic lymph node tumors: dosimetric evaluation of conventional proton therapy, proton arc therapy, and intensity modulated radiotherapy